NW006-296 / Chipscreen - LARVOL DELTA

NW006-296, a novel ROR1 targeting ADC, demonstrates compelling anti-tumor efficacy in preclinical studies (AACR 2026) - "When compared to the benchmark ADC (MK-2140), NW006-296 demonstrated superior anti-tumor activity in all CDX models investigated. NW006-296 has compelling anti-tumor efficacy and supports clinical development for ROR1-targeting ADCs across a broad spectrum of cancers. Further preclinical safety assessment, pharmacokinetics and IND-enabling studies are on-going with the goal to develop NW006-296 as a transformative therapeutic candidate for the treatment of colorectal cancer, breast cancer and hematological malignancies."

ADC • IO biomarker • Preclinical • Breast Cancer • Colorectal Cancer • Hematological Malignancies • Oncology • Solid Tumor • ROR1